1. Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
- Author
-
Gadelha, MR, Gu, F, Bronstein, M.D., Brue, T.C., Fleseriu, M, Shimon, I, Lely, A.J.D., Ravichandran, S., Kandra, A., Pedroncelli, A.M., Colao, A.A.L., Gadelha, MR, Gu, F, Bronstein, M.D., Brue, T.C., Fleseriu, M, Shimon, I, Lely, A.J.D., Ravichandran, S., Kandra, A., Pedroncelli, A.M., and Colao, A.A.L.
- Abstract
Pasireotide, a multireceptor-targeted somatostatin analog with highest affinity for somatostatin receptor subtype (SST) 5, has demonstrated superior efficacy over the SST2-preferential somatostatin analogs octreotide and lanreotide. The safety profile is similar to those of octreotide and lanreotide, except for a higher frequency and degree of hyperglycemia. This analysis investigated baseline characteristics and occurrence and management of hyperglycemia during pasireotide treatment in patients with acromegaly treated in two prospective clinical studies, SOM230C2305 (C2305) and SOM230C2402 (C2402; PAOLA). One hundred and seventy-eight patients naïve to medical therapy at baseline (C2305) and 125 uncontrolled on first-generation somatostatin analogs at baseline (C2402) received long-acting pasireotide in these studies. Of patients treated with pasireotide in studies C2305 and C2402, respectively, 75.3 (134/178) and 65.6% (82/125)
- Published
- 2020
- Full Text
- View/download PDF